Roivant Sciences Ltd. (ROIV): Shareholders' Equity
$4.53B
As of 2026-03-31
$4.23B
As of 2026-06-30
+57.5%
3-year compound annual growth
+20.3%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $4.53B | -3.4% | 2026-05-20, Balance as of period end |
| 2025-03-31 | $4.69B | -21.5% | 2026-05-20, Balance as of period end |
| 2024-03-31 | $5.97B | +415.5% | 2025-05-29, Balance as of period end |
| 2023-03-31 | $1.16B | -30.1% | 2024-05-30, Balance as of period end |
| 2022-03-31 | $1.66B | -7.8% | 2023-06-28, Balance as of period end |
| 2021-03-31 | $1.80B | n/a | 2022-06-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $4.53B | -3.4% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $43.03M | +8.7% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $103.08M | -33.7% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $26.50M | -53.7% |
| Adagene Inc. (ADAG) | 2025-12-31 | $35.35M | -30.0% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $272.05M | -15.8% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $581.76M | -22.9% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | -$4.06M | n/m |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $130.66M | +91.5% |
Compare ROIV, COYA, ACRS, BOLT side by side · Screen every company in Pharmaceutical Preparations ↗